The largest database of trusted experimental protocols

Rapid equilibrium dialysis device system

Manufactured by Thermo Fisher Scientific
Sourced in United States

The Rapid Equilibrium Dialysis Device System is a laboratory equipment designed for the evaluation of drug-protein binding. It facilitates the rapid establishment of equilibrium between a drug and its target protein, enabling researchers to determine the binding affinity and kinetics. The system provides a standardized platform for conducting these dialysis experiments.

Automatically generated - may contain errors

6 protocols using rapid equilibrium dialysis device system

1

Rapid Equilibrium Dialysis for Protein Binding

Check if the same lab product or an alternative is used in the 5 most similar protocols
The plasma protein fraction was determined using the Rapid Equilibrium Dialysis Device System (Life Technologies, Grand Island, NY) according to the manufacturer’s protocol. Membrane dialysis was performed with 10 μM of compound in mouse serum (500 μL) on one side of the membrane and PBS (750 μL) on the other side. The system was sealed with parafilm and incubated for 4 h at 37 °C on an orbital shaker set to 250 rpm. Thereafter, 400 μL of solution was taken from both sides, and samples were treated twice with an equal amount of AcN and vortexed to remove protein before HPLC analysis. After injection (100 μL), the I-PARPi peaks from each sample were then integrated and the protein bound fraction was determined. The data was analyzed using Prism 6.0c.
+ Open protocol
+ Expand
2

Rapid Equilibrium Dialysis of 19F-ATRi Protein Binding

Check if the same lab product or an alternative is used in the 5 most similar protocols
The plasma protein fraction was determined using the Rapid Equilibrium Dialysis Device System (Life Technologies, Grand Island, NY) according to the manufacturer’s protocol. Membrane dialysis was performed with 500 μM 19F–ATRi in serum (500 μL) on one side of the membrane and PBS (700 μL) on the other side. The system was sealed with parafilm and incubated for 4 h at 37 °C on an orbital shaker set to 100 rpm. Thereafter, 50 μL of solution was taken from both sides, and samples were treated with 300 μL of precipitation buffer (90/10 acetonitrile/water with 0.1% formic acid) and vortexed to remove protein before HPLC analysis. After injection, the [18F]-ATRi peaks from each sample were integrated, and the protein bound fraction determined as % bound = [1 – (Concentration buffer chamber/Concentration plasma chamber)]×100. The final albumin binding was calculated as the mean ± SD.
+ Open protocol
+ Expand
3

Rapid Equilibrium Dialysis for Plasma Protein Binding

Check if the same lab product or an alternative is used in the 5 most similar protocols
Plasma protein binding was assessed using the Rapid Equilibrium Dialysis Device system (Thermo Scientific, Rockford IL). The incubation was performed as described previously.(Haney et al., 2019 (link)) Briefly, mouse plasma (500 μL) was spiked separately with 20–223 at two concentrations (1 μg/mL and 10 μg/mL).The spiked 300 μL plasma sample was added to the donor chamber and 500 μL of phosphate-buffered saline (containing 100 mM sodium phosphate and 150 mM sodium chloride, pH 7.4) added to the buffer chamber. The plate was sealed and incubated at 37 °C on an orbital shaker at 100 rpm for 5 h. Aliquots (50 μL) were removed from the sample and buffer chambers and mixed with an equal volume of buffer or blank plasma, respectively. Calibration and QCs were prepared using equal volume of blank plasma and buffer. All matrix-matched samples were prepared as per described and analyzed by LC-MS/MS. Propranolol and atenolol were used as high and low protein bound positive controls. The stability, device recovery, and percent bound were calculated using following equation:
%Bound=ConcentrationdonorcellConentrationreceivercellConcentrationdonorcell×100
+ Open protocol
+ Expand
4

Compound Binding Kinetics in Plasma

Check if the same lab product or an alternative is used in the 5 most similar protocols
Animal plasmas (Innovative Research, Novi, MI, USA) and 5 μM of compounds were incubated in a rapid equilibrium dialysis device system (Thermo Fisher Scientific, Waltham, MA, USA) for 4 h. Cold acetonitrile was added to stop the reaction and the samples were centrifuged. The supernatant was analyzed using mass spectrometry with HPLC (Agilent).
+ Open protocol
+ Expand
5

Rapid Equilibrium Dialysis for Protein Binding

Check if the same lab product or an alternative is used in the 5 most similar protocols
Equilibrium dialysis experiments were carried out using the Rapid Equilibrium Dialysis (RED) Device System (Thermo Fischer Scientific, Waltham, MA, USA). ARP was added to 20-fold diluted plasma at a final concentration of 20 μM for sample preparation, and the sample was incubated for at least 1 h to reach equilibrium. The concentration of ARP was set in the detectable range of free bodies by our HPLC system. The same volume of samples and buffer solutions (67 mM sodium phosphate buffer (pH7.4), 0.3 mL) were inserted into each chamber which was separated by cellulose membranes and gently shaken at 25 °C for 4 h. After equilibrium was achieved, the ARP concentrations in the buffer (Cf; unbound drug concentration) and plasma protein compartments (20 times dilution of intact plasma: Cb+f; sum of −80 °C bound and unbound drug concentrations) were measured by HPLC. Bound concentration (Cb) was calculated by subtracting Cf from Cb+f. Plasma samples were diluted to avoid adsorption to the cells.
+ Open protocol
+ Expand
6

Plasma Protein Binding of Tozadenant

Check if the same lab product or an alternative is used in the 5 most similar protocols
The plasma protein binding of tozadenant (0.1 and 1 µg/mL) was determined by equilibrium dialysis in pooled Sprague-Dawley (SD) rat and human plasma. Equilibrium dialysis was performed using the Thermo Scientific™ Rapid Equilibrium Dialysis (RED) device system with 8 kDa molecular weight cutoff (Thermo Scientific, Rockford, IL, USA). Then, 300 µL of plasma sample containing tozadenant (0.1 and 1 µg/mL) was dialyzed against 500 µL of phosphate buffered saline (PBS) for 4 h at 37 °C. After the dialysis incubation time, the plasma samples were transferred to cluster tubes, and the same volume of PBS was added. In the same way, the PBS samples were transferred to cluster tubes, and the same volume of blank rat plasma was added to make the same matrix.
Then, all samples were prepared with the protein precipitation method followed by the LC-MS/MS analysis. The Fup of tozadenant in plasma was measured by calculating the ratio of tozadenant in PBS samples to plasma samples.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!